Skip Navigation

A Multi-Institutional Phase II Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

Brief Summary

Type:
Anus

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02314169

Study #:
STUDY00144041

Start Date:
Jun 26, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02314169

View Complete Trial Details & Eligibility at ClinicalTrials.gov